Cantor Fitzgerald analyst Jennifer Kim reiterates an Overweight rating and $15 price target on Checkpoint Therapeutics shares after the company announced its Biologics License Application submission for cosibelimab, its anti-PD-L1 antibody, for patients with metastatic cutaneous squamous cell carcinoma or locally advanced cSCC who are not candidates for curative surgery or radiation. Kim believes the completed BLA could also make potential BD opportunities more attractive, both in the U.S. and ex-U.S. Anti-PD-1/L1s remain foundational therapies, and continues to believe that cosibelimab’s clinical data to-date support an attractive profile as both monotherapy and in combination with other therapeutic modalities.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on CKPT:
- Checkpoint Therapeutics submits BLA to FDA for cosibelimab
- Checkpoint Therapeutics Submits Biologics License Application to FDA for Cosibelimab as a Treatment for Patients with Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma
- Checkpoint price target adjusted to $76 at H.C. Wainwright after reverse split
- Checkpoint Therapeutics price target raised to $15 from $7 at B. Riley
- Checkpoint Therapeutics announces $7.5M registered direct offering priced ATM